Merck Shares Outstanding 2006-2018 | MRK

Merck shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Merck shares outstanding for the quarter ending September 30, 2018 were 2.678B, a 1.8% decline year-over-year.
  • Merck 2017 shares outstanding were 2.748B, a 1.4% decline from 2016.
  • Merck 2016 shares outstanding were 2.787B, a 1.9% decline from 2015.
  • Merck 2015 shares outstanding were 2.841B, a 2.97% decline from 2014.
Merck Annual Shares Outstanding
(Millions of Shares)
2017 2,748
2016 2,787
2015 2,841
2014 2,928
2013 2,996
2012 3,076
2011 3,094
2010 3,120
2009 2,273
2008 2,143
2007 2,190
2006 2,188
2005 2,200
Merck Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 2,678
Q2 2018 2,696
Q1 2018 2,710
Q4 2017 2,748
Q3 2017 2,727
Q2 2017 2,752
Q1 2017 2,766
Q4 2016 2,787
Q3 2016 2,786
Q2 2016 2,789
Q1 2016 2,795
Q4 2015 2,841
Q3 2015 2,836
Q2 2015 2,850
Q1 2015 2,865
Q4 2014 2,928
Q3 2014 2,911
Q2 2014 2,949
Q1 2014 2,971
Q4 2013 2,996
Q3 2013 2,960
Q2 2013 3,010
Q1 2013 3,053
Q4 2012 3,076
Q3 2012 3,079
Q2 2012 3,072
Q1 2012 3,074
Q4 2011 3,094
Q3 2011 3,091
Q2 2011 3,110
Q1 2011 3,104
Q4 2010 3,120
Q3 2010 3,102
Q2 2010 3,125
Q1 2010 3,141
Q4 2009 2,273
Q3 2009 2,114
Q2 2009 2,110
Q1 2009 2,109
Q4 2008 2,143
Q3 2008 2,133
Q2 2008 2,152
Q1 2008 2,172
Q4 2007 2,190
Q3 2007 2,193
Q2 2007 2,189
Q1 2007 2,180
Q4 2006 2,188
Q3 2006 2,186
Q2 2006 2,188
Q1 2006 2,191
Q4 2005 2,200
Q3 2005 2,197
Q2 2005 2,206
Q1 2005 2,210
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $206.852B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.174B 18.29
Pfizer (PFE) United States $261.450B 14.74
Novartis AG (NVS) Switzerland $201.155B 17.24
AbbVie (ABBV) United States $130.807B 11.61
Eli Lilly (LLY) United States $120.318B 21.15
Novo Nordisk (NVO) Denmark $110.887B 18.01
Sanofi (SNY) France $109.052B 13.50
AstraZeneca (AZN) United Kingdom $96.706B 12.01
GlaxoSmithKline (GSK) United Kingdom $92.502B 12.43
Bristol-Myers Squibb (BMY) United States $86.637B 14.27